GO
Loading...

Gilead Sciences Inc

More

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • Final Glance: Biotechnology companies Thursday, 24 Jul 2014 | 6:22 PM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $122.26. Biogen Idec fell$. 81 or. 2 percent, to $336.79. Celgene Corp. fell $2.93 or 3.3 percent, to $86.19.

  • Midday Glance: Biotechnology companies Thursday, 24 Jul 2014 | 1:23 PM ET

    Biogen Idec fell$. 94 or. 3 percent, to $336.66. Celgene Corp. fell $3.22 or 3.6 percent, to $85.90. Gilead Sciences Inc. rose$. 04 or percent, to $90.38.

  • Most active Nasdaq-traded stocks Thursday, 24 Jul 2014 | 1:23 PM ET

    Apple Inc. fell. 2 percent to $97.03 with 44,545,900 shares traded. Ariad Pharmaceuticals Inc. rose 5.2 percent to $6.18 with 26,030,200 shares traded. BlackBerry Ltd. rose 5.6 percent to $10.38 with 31,147,300 shares traded.

  • July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

  • Early Glance: Biotechnology companies Thursday, 24 Jul 2014 | 11:37 AM ET

    Amgen Inc. fell$. 51 or. 4 percent, to $121.50. Biogen Idec rose$. 29 or. 1 percent, to $337.89. Celgene Corp. fell $3.63 or 4.1 percent, to $85.49.

  • July 23- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said.

  • Gilead profit more than quadruples on hep C drug Wednesday, 23 Jul 2014 | 5:11 PM ET

    FOSTER CITY, Calif.— Gilead Sciences Inc. on Wednesday reported profit that more than quadrupled in its second quarter, topping analysts' expectations on sales of its new breakthrough drug for hepatitis C.

  • July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • FDA approves Gilead Sciences drug for 3 cancers Wednesday, 23 Jul 2014 | 12:57 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. The FDA has approved three other drugs for the disease in the last year: Roche's Gazyva, Janssen Pharmaceutical's Imbruvica and GlaxoSmithKline's Arzerra.

  • As S&P nears 2,000, traders say keep an eye on this Wednesday, 23 Jul 2014 | 9:48 AM ET
    Traders work the floor of the New York Stock Exchange.

    Shaking off geopolitical flare-ups for now, analysts say the S&P 500 is taking aim at the 2,000 level, and the next round of earnings news could help.

  • Final Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 6:02 PM ET

    Amgen Inc. rose $2.08 or 1.7 percent, to $121.11. Biogen Idec rose $1.17 or. 4 percent, to $303.67. Celgene Corp. rose $1.35 or 1.6 percent, to $86.66.

  • Midday Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Amgen Inc. rose $1.68 or 1.4 percent, to $120.71. Biogen Idec rose $2.64 or. 9 percent, to $305.14. Celgene Corp. rose $1.30 or 1.5 percent, to $86.61.

  • Early Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 11:16 AM ET

    Amgen Inc. rose $1.30 or 1.1 percent, to $120.33. Biogen Idec rose $5.25 or 1.7 percent, to $307.75. Celgene Corp. rose $1.69 or 2.0 percent, to $87.00.

  • HIV pills show more promise to prevent infection Tuesday, 22 Jul 2014 | 2:31 AM ET

    There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • Midday movers: Blackstone, GE, RealPage & More Friday, 18 Jul 2014 | 12:44 PM ET
    Trader on the floor of the New York Stock Exchange.

    Some of Friday's midday movers:

  • US stocks mount strong rebound on company earnings Friday, 18 Jul 2014 | 8:53 AM ET

    The gains wiped out much of the market's losses from the day before, when the downing of a Malaysian Airlines passenger jet in eastern Ukraine stirred concerns that tensions between Russia and the West could escalate. Israel's launch of a ground offensive into Gaza also stoked geopolitical uncertainty.

  • July 17- UnitedHealth Group Inc, after wading cautiously into Obamacare insurance exchanges this year, on Thursday vowed to become a major player, participating in as many as two dozen state exchanges in 2015 and growing from there.

  • Sovaldi—$55 billion headache for states Thursday, 17 Jul 2014 | 10:18 AM ET

    States may be on the hook for $55 billion to pay for hepatitis C treatments like Sovaldi, a new study says.